Home > Insider Trading > Filing (0001387131-17-005721)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1173281	Ohr Pharmaceutical Inc	OHRP	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1131362	Orin Hirschman	C/O Ohr Pharmaceutical Inc. 800 Third Ave., 11Th Floor New York NY 10022		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2017-04-10	171,429	$0.70	1,678,177	No	4	P	Indirect	By AIGH Investment Partners, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By AIGH Investment Partners, LLC

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (right to buy)	Acquisiton	2017-04-10	120,001	$0.00	120,001	$1.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
120,001	2017-04-10	2022-04-10	No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	138,200	Indirect	By self as custodian of accounts for the benefit of minor children.

Footnotes

On April 5, 2017, Ohr Pharmaceutical, Inc. (the "Issuer") entered into a securities purchase agreement (the "Securities Purchase Agreement") with various purchasers set forth on the signatures pages thereto, including the Reporting Person. Pursuant to the Securities Purchase Agreement, the Reporting Person purchased shares of the Issuer's common stock (the "Common Stock") and warrants to purchase shares of Common Stock in a registered offering (the "Offering") for an aggregate purchase price of $120,000. The closing of the Offering occurred on April 10, 2017. The form 4 as originally filed underreported the Reporting Person's investment by $20,000, shares of common stock by 28,571, and shares of common stock issuable upon exercise of warrants by 20,000.